天香丹对冠心病患者血管生成因子影响的Meta分析  

Meta-analysis of effects of Tianxiangdan on angiogenic factors in patients with coronary heart disease

作　　者：谢阳 叶海涛 谢晓柳[1] 李秀芬[1] 吴丹丹 帕尔哈提·吐尔逊[1] 安冬青[2] XIE Yang;YE Haitao;XIE Xiaoliu;LI Xiufen;WU Dandan;Parhati Turson;AN Dongqing(The Affiliated Hospital of Traditional Chinese Medicine,Urumqi 830099,China;College of Traditional Chinese Medicine,Xinjiang Medical University,Urumqi 830017,China)

机构地区：[1]新疆医科大学附属中医医院,乌鲁木齐830099 [2]新疆医科大学中医学院,乌鲁木齐830017

出　　处：《新疆医科大学学报》2022年第7期780-784,共5页Journal of Xinjiang Medical University

基　　金：省部共建中亚高发病成因与防治国家重点实验室项目(SKL-HIDCA-2020-ZY21)。

摘　　要：目的系统评价天香丹对冠心病(Coronary heart disease,CHD)患者血管生成因子的影响,为天香丹治疗冠心病提供药理学依据。方法计算机检索中外文献数据库,检索时间为从建库至2021年9月30日,纳入有关天香丹治疗冠心病的随机对照试验,文献数据的提取及质量评价依据cochrane系统评价。采用RevMan5.3软件进行数据统计分析。结果共纳入符合要求的文献5篇,总计1345名研究对象。Meta分析结果显示:采用天香丹治疗的冠心病患者较对照组患者的血管内皮生长因子(Vascular endothelial growth factor,VEGF)水平[SMD=17.43,95%CI(2.14,32.72)]、一氧化氮(Nitric oxide,NO)水平[SMD=9.84,95%CI(5.31,14.37)]均显著提高(P<0.05),而一氧化氮合酶(Nitricoxide synthase,NOS)水平[SMD=0.17,95%CI(-0.02,0.37)]差异无统计学意义(P>0.05)。结论天香丹可有效提高冠心病患者血管生成因子VEGF及NO水平,从而改善冠心病相关临床症状。Objective To systematically evaluate the effect of Tianxiangdan on angiogenic factors in patients with coronary artery disease,and to provide a modern pharmacological basis for treatment of coronary artery disease with Tianxiangdan.Methods All studies were searched from databases of Pubmed,Cochrane Library,CNKI,VIP and Wanfang from the beginning to September 2021.The literature involving clinical randomized controlled trials of Tianxiangdan in the treatment of coronary heart disease were collected.Literature data extraction and quality assessment were performed according to cochrane systematic evaluation method.Statistical analysis carried out with using RevMan 5.3 software.Results A total of 5 papers were eventually included that met related requirements with involving 1345 participants.Meta-analysis results showed that vascular endothelial growth factor levels and nitric oxide levels were significantly higher in CHD patients treated with Tianxiangdan than in the control group(P<0.05),the difference in nitric oxide synthase levels was not significant between the two groups(P>0.05),SMD were 17.43,95%CI(2.14,32.72),9.84,95%CI(5.31,14.37)and 0.17,95%CI(-0.02,0.37)respectively.Conclusion Tianxiangdan can effectively improve the levels of angiogenic factor VEGF and NO in patients with coronary heart disease,thus it could improve the clinical symptoms related to coronary heart disease.

关 键 词：冠心病 血管生成因子 META分析 

分 类 号：R256.21[医药卫生—中医内科学]